Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. All that Glitters is Not Gold… It’s true,
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate levels over a five-year period from 2012 to 2017. In addition, the study analyzes a number of Medicare Part B
The new Biden administration has started off strong, taking a thoughtful approach to any number of critical health care issues and pulling back a number of new regulations to take a fresh look at these public policy issues. To avoid
(Washington, D.C.) — Today, the U.S. House of Representatives passed a legislative package, SUPPORT for Patients and Communities Act (H.R. 6), which requires electronic prescribing (e-prescribing) of controlled substances in Medicare. This is an important step in the fight against America’s
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a Medicare Part D report released today by the Office of Inspector (OIG), U.S. Department of Health and Human Services (HHS): “This report finally debunks the myth
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from IQVIA Institute for Human Data Science, 2018 and Beyond: Outlook and Turning Points. Key findings from the report include: Rebates and discounts
Alex Brill and Angela Banks Dive into the Critical Need for Competition, Big Drug Companies’ Abuse of the Patent System, and Biosimilar Adoption In case you missed it, Angela Banks, Vice President of Policy for the Pharmaceutical Care Management Association
Hearing Confirms Big Drug Companies Would Benefit from Misguided Proposals Targeting Pharmacy Benefits This week, the U.S. House Committee on Oversight and Accountability held a hearing where lawmakers and an expert witness, Frederick Isasi, JD, MPH, executive director of Families
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the House Democrats drug pricing legislation: “We appreciate House Speaker Nancy Pelosi’s and the House Democratic leadership’s focus on reducing prescription drug prices,
©2024 PCMA. All Rights Reserved.
